JP2013510122A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510122A5
JP2013510122A5 JP2012537380A JP2012537380A JP2013510122A5 JP 2013510122 A5 JP2013510122 A5 JP 2013510122A5 JP 2012537380 A JP2012537380 A JP 2012537380A JP 2012537380 A JP2012537380 A JP 2012537380A JP 2013510122 A5 JP2013510122 A5 JP 2013510122A5
Authority
JP
Japan
Prior art keywords
phenyl
methyl
alkyl
triazolo
benzodiazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012537380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510122A (ja
Filing date
Publication date
Priority claimed from GBGB0919426.7A external-priority patent/GB0919426D0/en
Application filed filed Critical
Publication of JP2013510122A publication Critical patent/JP2013510122A/ja
Publication of JP2013510122A5 publication Critical patent/JP2013510122A5/ja
Withdrawn legal-status Critical Current

Links

JP2012537380A 2009-11-05 2010-11-03 ブロモドメイン阻害剤としての縮合アゼピン誘導体 Withdrawn JP2013510122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0919426.7A GB0919426D0 (en) 2009-11-05 2009-11-05 Novel compounds
GB0919426.7 2009-11-05
PCT/EP2010/066696 WO2011054844A1 (en) 2009-11-05 2010-11-03 Condensed azepine derivatives as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
JP2013510122A JP2013510122A (ja) 2013-03-21
JP2013510122A5 true JP2013510122A5 (enExample) 2013-11-28

Family

ID=41501969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537380A Withdrawn JP2013510122A (ja) 2009-11-05 2010-11-03 ブロモドメイン阻害剤としての縮合アゼピン誘導体

Country Status (5)

Country Link
US (1) US20120202799A1 (enExample)
EP (1) EP2496581A1 (enExample)
JP (1) JP2013510122A (enExample)
GB (1) GB0919426D0 (enExample)
WO (1) WO2011054844A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
MX362384B (es) 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2013033269A1 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN104334526A (zh) 2012-04-20 2015-02-04 艾伯维公司 异吲哚酮衍生物
TWI602820B (zh) * 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
RU2632915C2 (ru) 2012-06-12 2017-10-11 Эббви Инк. Производные пиридинона и пиридазинона
EP2861255B1 (en) 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
KR20150041787A (ko) 2012-08-16 2015-04-17 바이엘 파마 악티엔게젤샤프트 2,3-벤조디아제핀
JP6276277B2 (ja) 2012-09-28 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト Betタンパク質阻害性の5−アリールトリアゾロアゼピン
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US10035800B2 (en) * 2013-03-12 2018-07-31 Abbvie Inc. Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
BR112015022417A2 (pt) 2013-03-14 2017-07-18 Convergene Llc métodos e composições para inibição de proteínas contendo bromodomínio
CA2903881C (en) 2013-03-15 2021-05-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3099696A4 (en) 2014-01-31 2017-07-05 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
AU2015222805B2 (en) * 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2015156601A1 (en) * 2014-04-09 2015-10-15 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
WO2015164480A1 (en) 2014-04-23 2015-10-29 Incyte Corporation 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
BR112017002190A2 (pt) 2014-08-08 2017-11-21 Dana Farber Cancer Inst Inc derivados de di-hidropteridinona e usos dos mesmos
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP2018520124A (ja) 2015-06-26 2018-07-26 テンシャ セラピューティクス,インコーポレイテッド Nut正中線癌の治療
EP3334725B1 (en) 2015-08-10 2025-04-23 Dana-Farber Cancer Institute, Inc. Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer
WO2017037567A1 (en) * 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
JP2019500336A (ja) 2015-12-03 2019-01-10 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺虫剤としてのメソイオン性ハロゲン化3−(アセチル)−1−[(1,3−チアゾール−5−イル)メチル]−1H−イミダゾ[1,2−a]ピリジン−4−イウム−2−オレート誘導体及び関連する化合物
WO2017142881A1 (en) 2016-02-15 2017-08-24 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Mdm2タンパク質分解剤
UA123168C2 (uk) 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
ES2793239T3 (es) 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
SMT202300155T1 (it) 2016-06-20 2023-07-20 Incyte Corp Forme solide cristalline di un inibitore di bet
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
JP7035027B2 (ja) 2016-09-13 2022-03-14 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betタンパク質分解物質としての縮合1,4-ジアゼピン
CN110062759B (zh) 2016-09-13 2022-05-24 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
EP3577120A1 (en) 2017-02-03 2019-12-11 The Regents of The University of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
US20210179620A1 (en) 2017-06-16 2021-06-17 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
CN112867705B (zh) 2018-04-04 2024-08-20 埃皮欧黛公司 阿片样物质受体调节剂以及与其相关的产品和方法
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2023532233A (ja) 2020-06-23 2023-07-27 ジェネンテック, インコーポレイテッド 大環状化合物及びその使用方法
TW202304869A (zh) 2021-04-05 2023-02-01 美商艾碧奧戴股份有限公司 類鴉片受體調節劑
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023205251A1 (en) 2022-04-19 2023-10-26 Nuevolution A/S Compounds active towards bromodomains

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CA2120939A1 (en) * 1991-10-11 1993-04-15 Tetsuya Tahara Therapeutic agent for osteoporosis and diazepine compound
JPH06128257A (ja) * 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
US5679672A (en) * 1993-11-22 1997-10-21 Merck & Co., Inc. Benzodiazepines
CN1227555A (zh) * 1996-06-12 1999-09-01 日本烟草产业株式会社 细胞因子生成抑制剂、三氮䓬化合物及其中间体
PT1699512E (pt) 2003-11-03 2012-09-11 Glaxo Group Ltd Dispositivo distribuidor de fluido
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent

Similar Documents

Publication Publication Date Title
JP2013510122A5 (enExample)
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
JP2016523923A5 (enExample)
JP2014502979A5 (enExample)
JP2013510123A5 (enExample)
JP2017523972A5 (enExample)
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
JP2014511892A5 (enExample)
JP2014511891A5 (enExample)
JP2011529037A5 (enExample)
JP2012508252A5 (enExample)
RU2010122333A (ru) Ингибиторы цитокинов
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
JP2013543896A5 (enExample)
JP2005535586A5 (enExample)
CA2660529A1 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
SI2824100T1 (en) 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
RU2009142434A (ru) Производные триазолопиридин-карбоксамидов и триазолопиримидин-карбоксамидов, их получение и их применение в терапии
JP2010500345A5 (enExample)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
JP2007520440A5 (enExample)
RU2014101464A (ru) Циклопропил-конденсированные-1,3-тиазепины в качестве ингибиторов васе 1 и(или) васе 2
JP2010536821A5 (enExample)
JP2011511845A5 (enExample)
JP2020521772A5 (enExample)